Skip to content

Effect of silymarin topical gel compared to placebo topical gel as adjunctive therapy on pain control after stroke

Effect of silymarin topical gel compared to placebo topical gel as adjunctive therapy on pain control after stroke: a double-blind randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120215009014N559
Enrollment
50
Registered
2025-05-21
Start date
2025-08-23
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke. Cerebellar stroke syndrome

Interventions

Intervention 1: Intervention group: Standard treatment included pregabalin tablets 50 to 75 mg twice daily and duloxetine tablets 20 mg twice daily for 3 months plus 3% silymarin topical gel on the sh

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age 18 to 75 years Stroke Shoulder and scapula muscle pain and stiffness

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Kidney or liver failure Use of painkillers Substance abuse

Design outcomes

Primary

MeasureTime frame
Mean pain score. Timepoint: Before intervention and 3 months later. Method of measurement: Using Visual Analog Scale (VAS).;Degree and frequency of muscle cramps. Timepoint: Before intervention and 3 months later. Method of measurement: Using clinical examination.

Secondary

MeasureTime frame
Local complications (redness, burning, itching). Timepoint: 3 months after intervention. Method of measurement: By taking history.;Mean quality of life score. Timepoint: Before intervention and 3 months later. Method of measurement: Using World Health Organization Quality of Life Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedeh Zahra Mousavi Golbar

Hamedan University of Medical Sciences

shokranemosavi32@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026